GO:0042627 chylomicron: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042627 chylomicron describes a large lipoprotein particle (75-1200 nm) with a triglyceride- and cholesterol-rich core surrounded by a protein-phospholipid coat, found in blood or lymph.
• Each chylomicron contains one molecule of apolipoprotein B-48 (APOB-48) and may also carry APOA, APOC and APOE family apolipoproteins.
• Chylomicrons are assembled in enterocytes, secreted into lymph, and deliver dietary lipids to peripheral tissues before remnant uptake by the liver.
• Post-assembly secretion is a regulated, rate-limiting step involving GTPases, cytoskeletal motors and vesicular trafficking machinery.
• Chylomicron metabolism is central to postprandial lipemia, and impaired clearance is linked to cardiometabolic risk.
• CRISPR knockout, knock-in, point-mutation and overexpression models enable causal testing of chylomicron-related genes in enterocyte and hepatocyte systems.
Description
Chylomicrons are the largest lipoprotein particles in the circulation and the primary vehicles for transporting dietary fat and fat-soluble nutrients from the intestine to the rest of the body. In the Gene Ontology, they are annotated as a cellular component under GO:0042627, reflecting their status as a defined, membrane-bound-like particle with a characteristic protein and lipid composition. Because chylomicron biology sits at the intersection of lipid absorption, energy storage and cardiovascular risk, it is a recurring focus for researchers in gastroenterology, endocrinology and vascular biology. Understanding how chylomicrons are assembled, secreted and cleared requires integrating cell biology, physiology and genetics, and the GO term provides a shared vocabulary for annotating genes and proteins that localize to or act upon this particle. This article summarizes the authoritative definition, the major molecular players, disease links and the experimental methods, including CRISPR-based models, used to study chylomicrons.
chylomicron At A Glance
| GO ID | GO:0042627 |
|---|---|
| GO term | chylomicron |
| Ontology | cellular_component |
| Synonym | none listed in QuickGO |
| Major function | Transport of dietary lipids from intestine to peripheral tissues via blood or lymph |
| Particle size | Diameter 75-1200 nm |
| Core composition | Triglycerides and cholesterol |
| Surface composition | Protein-phospholipid coating including one molecule of APOB-48 |
| Other apolipoproteins | May include APOAs, APOCs and APOE |
| Location | Blood or lymph |
What Is GO:0042627?
According to the QuickGO definition, GO:0042627 chylomicron is a large lipoprotein particle with a diameter of 75-1200 nm, composed of a central core of triglycerides and cholesterol surrounded by a protein-phospholipid coating. The particle contains one molecule of apolipoprotein B-48 and may include a variety of other apolipoproteins such as APOAs, APOCs and APOE. Chylomicrons are found in blood or lymph and function to carry lipids from the intestines into other body tissues.
Why Is chylomicron Important in Cell Biology?
Chylomicrons are the obligatory carriers of dietary fat and fat-soluble vitamins, so their assembly, secretion and clearance directly determine postprandial lipid handling and systemic energy distribution. Defects in chylomicron metabolism cause severe hypertriglyceridemia and are associated with pancreatitis and atherosclerotic risk, while efficient chylomicron remnant clearance is protective. Because the particle is a discrete, measurable entity, it is also a powerful experimental readout for gene function in lipid transport.
• Chylomicrons mediate absorption and systemic delivery of dietary triglycerides and cholesterol.
• They are the major determinant of postprandial lipemia, a recognized cardiometabolic risk factor.
• APOB-48 is the obligatory structural apolipoprotein of chylomicrons and a key genetic marker.
• Chylomicron secretion is a regulated, post-assembly process amenable to genetic dissection.
• Chylomicron remnants contribute to atherogenic lipid pools after partial lipolysis.
• Chylomicron-treated endothelial cells release extracellular vesicles that drive macrophage inflammation.
• The particle is a cellular-component annotation hub linking lipid genes to a defined subcellular entity.
• Chylomicron biology is relevant to malabsorption, hypertriglyceridemia and pancreatitis research.
• CRISPR models allow causal testing of candidate genes in chylomicron assembly and secretion.
• Quantitative imaging and lipidomics make chylomicrons a tractable phenotype for functional genomics.
Structure and Composition of chylomicron
Core lipid cargo
In simple terms: The inside of a chylomicron is a fat droplet made mainly of triglycerides and cholesterol.
Chylomicrons have a central core composed of triglycerides and cholesterol, which represents the transported lipid cargo. This hydrophobic core is stabilized by a surface monolayer, and its size varies with the amount of lipid absorbed, giving the particle its broad 75-1200 nm diameter range.
APOB-48 structural scaffold
In simple terms: APOB-48 is the one protein that every chylomicron must carry to be built.
Each chylomicron contains one molecule of apolipoprotein B-48, which is the obligatory structural apolipoprotein and is essential for particle assembly and secretion by enterocytes. APOB-48 is produced by intestinal editing of the APOB transcript and lacks the LDL-receptor-binding domain of APOB-100.
Exchangeable apolipoproteins
In simple terms: Other apolipoproteins can hop onto the particle surface and change how it is processed.
In addition to APOB-48, chylomicrons may include a variety of apolipoproteins such as APOAs, APOCs and APOE. These exchangeable apolipoproteins modulate lipase activity, receptor recognition and remnant clearance, and their presence varies with metabolic state.
Protein-phospholipid surface coat
In simple terms: A shell of phospholipids and proteins keeps the fat core mixed with the watery blood.
The particle is surrounded by a protein-phospholipid coating that emulsifies the hydrophobic core and presents apolipoproteins to plasma enzymes and receptors. This surface monolayer is the interface where lipoprotein lipase and other factors act during lipolysis.
Assembly in the enterocyte
In simple terms: Chylomicrons are built inside intestinal cells before being exported.
Chylomicron assembly occurs in enterocytes and involves coordinated lipid esterification, APOB-48 synthesis and packaging into a secretory particle. The intracellular route from the endoplasmic reticulum to the secretory pathway is an active area of investigation, and post-assembly steps are rate-limiting for secretion.
Secretion into lymph and blood
In simple terms: Once built, chylomicrons leave the intestine through lymph and enter the bloodstream.
Chylomicrons are secreted into lymph and then enter the blood, where they circulate as large particles that carry lipids from the intestines to other body tissues. Secretion depends on vesicular trafficking and cytoskeletal transport mechanisms that are regulated independently of particle assembly.
Key Genes Involved in GO:0042627 chylomicron
The following genes and proteins are recurrently implicated in chylomicron assembly, secretion, remodeling and clearance based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Encodes APOB-48, the obligatory structural apolipoprotein of chylomicrons | Core marker for chylomicron assembly and secretion studies |
| MTTP | Microsomal triglyceride transfer protein required for APOB lipidation and chylomicron assembly | Loss-of-function causes abetalipoproteinemia; key assembly gene |
| APOA4 | Exchangeable apolipoprotein that modulates chylomicron metabolism | Candidate modifier of postprandial lipemia |
| APOA5 | Regulates plasma triglyceride levels and chylomicron clearance | Genetic variant linked to hypertriglyceridemia risk |
| APOC2 | Activates lipoprotein lipase for chylomicron triglyceride hydrolysis | Deficiency causes severe hypertriglyceridemia |
| APOC3 | Inhibits lipoprotein lipase and hepatic remnant uptake | Therapeutic target for triglyceride lowering |
| APOE | Mediates chylomicron remnant receptor recognition | Isoform variation affects remnant clearance |
| LPL | Lipoprotein lipase hydrolyzes chylomicron core triglycerides | Central enzyme in chylomicron lipolysis |
| GPIHBP1 | Endothelial platform that anchors lipoprotein lipase | Required for efficient chylomicron processing |
| LMF1 | Lipase maturation factor required for LPL activity | Mutations cause hypertriglyceridemia |
| SAR1B | GTPase involved in COPII-dependent chylomicron secretion | Mutations cause chylomicron retention disease |
| RAB proteins | Regulate vesicular trafficking of chylomicron carriers | Post-assembly secretion regulators |
| VAMP7 | SNARE protein implicated in chylomicron secretory vesicle fusion | Candidate for secretion control studies |
| CD36 | Fatty acid uptake and chylomicron-related lipid sensing | Links lipid uptake to particle formation |
| CREB3L3 | Transcription factor regulating lipid and lipoprotein genes | Transcriptional control of chylomicron secretion |
| ANGPTL4 | Inhibits lipoprotein lipase and modulates chylomicron clearance | Postprandial lipid regulator |
| NR1H2/NR1H3 | Nuclear receptors influencing lipid transport gene expression | Upstream regulators of chylomicron pathways |
| ABCA1 | Lipid efflux transporter affecting lipoprotein metabolism | Modifies chylomicron-related lipid flux |
How Is chylomicron Regulated?
Chylomicron secretion is regulated at multiple levels, and post-assembly mechanisms are now recognized as a major control point. GTPase-dependent budding, cytoskeletal transport and SNARE-mediated fusion govern the exit of chylomicron carriers from enterocytes, and these steps can be modulated independently of lipid absorption. Transcriptional regulators such as CREB3L3 influence the expression of genes required for lipoprotein assembly and secretion. In the circulation, lipoprotein lipase activity is controlled by APOC2, APOC3, APOA5, ANGPTL4 and the endothelial anchor GPIHBP1, which together set the rate of chylomicron triglyceride hydrolysis and remnant formation. Postprandial metabolism therefore reflects a balance between secretion, lipolysis and receptor-mediated remnant uptake.
chylomicron and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOB | Chylomicron assembly failure and hypobetalipoproteinemia | Enterocyte knockout and knock-in of APOB variants |
| MTTP | Abetalipoproteinemia with defective chylomicron assembly | Knockout cell model with lipid loading assays |
| SAR1B | Chylomicron retention disease | Point-mutation knock-in of patient variants |
| LPL | Severe hypertriglyceridemia and pancreatitis risk | Overexpression and point-mutation models in lipid-handling cells |
| APOC3 | Hypertriglyceridemia via lipoprotein lipase inhibition | Knockout and overexpression models for triglyceride secretion |
Hypertriglyceridemia and pancreatitis
Impaired chylomicron lipolysis or clearance causes accumulation of triglyceride-rich particles and severe hypertriglyceridemia, a recognized risk factor for acute pancreatitis. Genes such as LPL, APOC2, APOA5, GPIHBP1 and LMF1 are implicated in these disorders, and chylomicron metabolism is therefore a direct therapeutic focus.
Atherosclerosis and vascular inflammation
Chylomicron remnants contribute to atherogenic lipid pools, and recent work shows that extracellular vesicles from chylomicron-treated endothelial cells drive macrophage inflammation. This links postprandial chylomicron handling to vascular inflammatory processes relevant to atherosclerosis research.
Chylomicron retention and malabsorption
Defects in chylomicron assembly or secretion, such as those involving SAR1B, impair lipid export from enterocytes and cause chylomicron retention disease with fat malabsorption. Studying the intracellular chylomicron highway has clarified how secretory pathway defects produce this phenotype.
Postprandial cardiometabolic risk
Because chylomicrons dominate postprandial lipemia, their kinetics are increasingly viewed as a modifiable contributor to cardiometabolic risk beyond fasting lipid measures. This has motivated research into postprandial metabolism as a distinct clinical and experimental target.
From chylomicron-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for chylomicron secretion? | CRISPR knockout in enterocyte-like cells with lipid-loading readouts |
| Does a patient variant impair APOB-48 function? | Point-mutation knock-in of the variant allele |
| Can a protective allele enhance chylomicron clearance? | Knock-in of the variant with lipoprotein lipase activity assays |
| Where does a protein localize during chylomicron assembly? | Tagged knock-in with fluorescence imaging |
| Does overexpression of a regulator increase particle output? | Stable overexpression in lipid-secreting cell models |
| Which genes modify postprandial lipemia? | CRISPR library screening with lipid flux selection |
How to Study the chylomicron Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Triglyceride and lipoprotein profiling | Postprandial lipid levels and particle abundance | Phenotyping genetic models of chylomicron metabolism |
| Fluorescence imaging | Localization and trafficking of chylomicron carriers | Dissecting assembly and secretion steps |
| Proteomics | Apolipoprotein composition of particles | Defining chylomicron protein content |
| Lipidomics | Core and surface lipid species | Linking lipid cargo to particle function |
| CRISPR knockout | Loss-of-function effects on particle secretion | Testing candidate gene requirement |
| Knock-in of variants | Allele-specific effects on chylomicron handling | Modeling patient variants |
| Overexpression | Gain-of-function effects on lipid transport | Testing sufficiency of regulators |
| Library screening | Genome-wide modifiers of lipid flux | Discovery of new chylomicron regulators |
Lipid and lipoprotein quantification
Chylomicron production and clearance are typically assessed by measuring triglyceride-rich particles in blood or lymph after a fat load, which captures the postprandial phenotype central to this GO term. These measurements provide the primary readout for genetic perturbation experiments.
Imaging of particle assembly and trafficking
Fluorescence and electron microscopy of tagged apolipoproteins and secretory carriers reveal where chylomicrons are assembled and how they move through the enterocyte. Live-cell imaging of the intracellular chylomicron highway has become a key approach for dissecting post-assembly steps.
Proteomics and lipidomics
Mass spectrometry-based proteomics identifies the apolipoprotein composition of isolated particles, while lipidomics defines core and surface lipid species. These methods connect the GO annotation to measurable molecular composition.
Genetic perturbation and screening
CRISPR knockout, knock-in and overexpression combined with lipid readouts allow causal testing of candidate genes in chylomicron biology. Pooled library screening can nominate new regulators of secretion and clearance for follow-up.
How CRISPR Can Be Used to Study GO:0042627 chylomicron
Knockout
CRISPR knockout of candidate genes in enterocyte-like or hepatocyte-like cells can test whether a factor is required for chylomicron assembly or secretion, using triglyceride secretion and particle quantification as readouts. This approach is well suited to validating genes implicated in post-assembly trafficking.
Point Mutation
Point-mutation knock-in allows modeling of patient variants in genes such as APOB, SAR1B or LPL, revealing allele-specific effects on particle formation and clearance. Such models preserve endogenous regulation and are valuable for mechanistic interpretation of genetic findings.
Knock-in
Tagged knock-in of apolipoproteins or trafficking proteins enables direct visualization and purification of chylomicron-related complexes in their native context. This supports imaging and proteomic studies of the intracellular chylomicron pathway.
Overexpression
Overexpression of regulators such as apolipoproteins or lipase modulators can test sufficiency for increased or decreased chylomicron secretion and clearance. Combined with lipid readouts, overexpression models complement loss-of-function studies.
How EDITGENE Supports chylomicron Research
Researchers studying chylomicron-related genes often need to determine whether a candidate gene is causally involved in particle assembly, secretion or clearance rather than merely correlated with a lipid phenotype. EDITGENE provides the CRISPR cell models and screening services needed to move from association to mechanism in chylomicron biology.
Contact EDITGENE today to design your custom CRISPR model for chylomicron research.
Frequently Asked Questions About chylomicron
What is GO:0042627 chylomicron?
GO:0042627 chylomicron is a Gene Ontology cellular-component term describing a large lipoprotein particle (75-1200 nm) with a triglyceride and cholesterol core, a protein-phospholipid coat, one molecule of APOB-48, and possible APOA, APOC and APOE apolipoproteins, found in blood or lymph.
What genes are involved in chylomicron biology?
Key genes include APOB, MTTP, SAR1B, APOA4, APOA5, APOC2, APOC3, APOE, LPL, GPIHBP1, LMF1 and trafficking regulators such as RAB proteins and VAMP7.
Where are chylomicrons made?
Chylomicrons are assembled in enterocytes and secreted into lymph before entering the blood to deliver dietary lipids to tissues.
What is the function of APOB-48 in chylomicrons?
APOB-48 is the obligatory structural apolipoprotein present as one molecule per chylomicron and is required for particle assembly and secretion.
How are chylomicrons cleared from the blood?
Lipoprotein lipase hydrolyzes core triglycerides, and the resulting remnants are taken up by the liver through receptor-mediated pathways involving APOE and related factors.
Why is chylomicron metabolism important for disease?
Defective chylomicron lipolysis or clearance causes hypertriglyceridemia and pancreatitis risk, and remnants contribute to atherosclerosis and vascular inflammation.
What is chylomicron retention disease?
It is a disorder caused by defects in chylomicron assembly or secretion, such as SAR1B mutations, leading to impaired lipid export from enterocytes and fat malabsorption.
How do researchers study chylomicron secretion?
They use lipid and lipoprotein profiling, imaging of tagged proteins, proteomics, lipidomics and CRISPR perturbation with triglyceride secretion readouts.
Can CRISPR be used to model chylomicron disorders?
Yes, CRISPR knockout, knock-in, point-mutation and overexpression models allow causal testing of genes involved in chylomicron assembly, secretion and clearance.
What is postprandial lipemia in relation to chylomicrons?
Postprandial lipemia refers to the rise in triglyceride-rich particles, mainly chylomicrons, after a meal, and it is increasingly studied as a cardiometabolic risk factor.
Conclusion
GO:0042627 chylomicron defines a large, apolipoprotein-coated lipid particle that is central to dietary fat transport and postprandial metabolism. Its composition, assembly and clearance are governed by a well-characterized set of genes and regulatory steps, and defects in these processes underlie hypertriglyceridemia, malabsorption and vascular inflammation. CRISPR-based cell models and screening provide a direct route to test causality for chylomicron-related candidate genes.
References
- 1. Xiao C et al.. 2019. Regulation of Chylomicron Secretion: Focus on Post-Assembly Mechanisms.. Cell Mol Gastroenterol Hepatol 7(3):487-501 PMID: 30819663
- 2. Gugliucci A. 2023. The chylomicron saga: time to focus on postprandial metabolism.. Front Endocrinol (Lausanne) 14:1322869 PMID: 38303975
- 3. Redgrave TG. 2004. Chylomicron metabolism.. Biochem Soc Trans 32(Pt 1):79-82 PMID: 14748717
- 4. Visser A et al.. 2025. The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion.. Curr Opin Lipidol 36(3):145-152 PMID: 40152288
- 8. Tilp A et al.. 2025. Extracellular Vesicles From Chylomicron-Treated Endothelial Cells Drive Macrophage Inflammation.. Arterioscler Thromb Vasc Biol 45(12):2179-2195 PMID: 41099102
